ArticleTherapeutic advances in urology
Renal metastasis of adenocarcinoma of the gastrointestinal tract with unknown primary site: a case report and review of the literature.
Article in Therapeutic advances in urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer of unknown primary (CUP) is an aggressive malignancy with a persistently poor prognosis. Renal metastases from an occult primary adenocarcinoma are exceptionally rare and diagnostically challenging, frequently mimicking primary kidney cancer. This case report details a rare instance of metastatic adenocarcinoma to the kidney from an occult primary origin, initially misclassified as primary renal cell carcinoma. A 60-year-old male patient was admitted to our department for further evaluation of a cystic-solid right renal mass. Staging revealed synchronous extrarenal metastases. Subsequent immunohistochemical analysis indicated gastrointestinal differentiation, yet exhaustive diagnostic workup failed to identify the primary tumor site. The patient underwent radical nephrectomy followed by biomarker-guided FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy combined with camrelizumab immunotherapy, achieving a progression-free survival of approximately 7 months, accompanied by a temporary decline in tumor markers. Tumor recurrence manifested at 11 months postoperatively as pulmonary progression, at which point retrospective molecular profiling of the archived specimen revealed an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.